Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Preferred Shares (2017 - 2021)

Avalo Therapeutics' Preferred Shares history spans 5 years, with the latest figure at $1000.0 for Q1 2021.

  • For Q1 2021, Preferred Shares fell 20.45% year-over-year to $1000.0; the TTM value through Mar 2021 reached $1000.0, down 20.45%, while the annual FY2020 figure was $1000.0, 65.0% down from the prior year.
  • Preferred Shares reached $1000.0 in Q1 2021 per AVTX's latest filing, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $2857.0 in Q4 2018 to a low of $4.0 in Q1 2017.
  • Average Preferred Shares over 5 years is $1672.0, with a median of $1257.0 recorded in 2020.
  • Peak YoY movement for Preferred Shares: changed 0.0% in 2019, then plummeted 65.0% in 2020.
  • A 5-year view of Preferred Shares shows it stood at $4.0 in 2017, then soared by 71325.0% to $2857.0 in 2018, then changed by 0.0% to $2857.0 in 2019, then crashed by 65.0% to $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2021.
  • Per Business Quant, the three most recent readings for AVTX's Preferred Shares are $1000.0 (Q1 2021), $1000.0 (Q4 2020), and $1257.0 (Q3 2020).